via EPFL
Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
More from: École Polytechnique Fédérale de Lausanne | Lausanne University Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Monoclonal antibody
- Scientists design two-in-one antibodies against COVID-19 variants
A medical worker takes a swab sample from a citizen for nucleic acid testing at Heping District in Tianjin, north China, July 24, 2022. (Xinhua/Sun Fanyue) BEIJING, Aug. 2 (Xinhua) -- Chinese ...
- Progress In The Search For Broadly Neutralizing Monoclonal Antibodies V
Antibodies from vaccines wane after a few months, antibodies from previous infections are often ineffective, and monoclonal therapies that worked against earlier variants struggle against current ...
- Half of the population of Geneva have antibodies that neutralize omicron variants
A study by the Geneva University Hospitals (HUG), the Faculty of Medicine of the University of Geneva (UNIGE) and the EPFL shows that almost all Genevans (93.8%) have antibodies against SARS-CoV 2, ...
- Cross-reactive SARS-CoV-2 antibodies after exposure to avian coronavirus vaccine
Researchers identify SARS-CoV-2 cross-reactive antibodies in poultry farm workers exposed to the avian infectious bronchitis virus.
- The kinetics of SARS-CoV-2 nucleocapsid antibodies up to 21 months after infection
Antibodies could help identify past infection, and population-level serologic studies have often been used to measure antibody levels for different pathogens. Such studies provide critical inputs ...
Go deeper with Google Headlines on:
Monoclonal antibody
Go deeper with Bing News on:
SARS-CoV-2 monoclonal antibody
- How and when do de novo SARS-CoV-2 spike mutations emerge?
Mutations in SARS-CoV-2 have been associated with enhanced transmissibility, immune escape, resistance to therapeutics, and impaired diagnostic detection. Several SARS-CoV-2 variants of concern (VOCs) ...
- Progress In The Search For Broadly Neutralizing Monoclonal Antibodies V
Antibodies from vaccines wane after a few months, antibodies from previous infections are often ineffective, and monoclonal therapies that worked against earlier variants struggle against current ...
- The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency
A recent study published in Nature Microbiology identified a monoclonal antibody (mAb) neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants. Study ...
- CNBG’s monoclonal antibody against Omicron variants approved for clinical trials
A monoclonal antibody against SARS-CoV-2 has been approved by China's medical authorities for clinical trials, which is of great significance for coping with the spread of Omicron variants, said an ...
- Research team demonstrates rapid clearance of culturable SARS-CoV-2 following monoclonal antibody treatment
While bamlanivimab is not currently in clinical use, the identical mechanisms of action of all clinically used SARS-CoV-2-targeting monoclonal antibodies make it likely that these findings will ...